<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="Nystatin" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">livertox</book-id>
    <book-title-group>
      <book-title>LiverTox</book-title>
      <subtitle>Clinical and Research Information on Drug-Induced Liver Injury</subtitle>
    </book-title-group>
    <pub-date date-type="pubr" publication-format="electronic">
      <year>2012</year>
    </pub-date>
    <publisher>
      <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
      <publisher-loc>Bethesda (MD)</publisher-loc>
    </publisher>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">Nystatin</book-part-id>
      <title-group>
        <title>Nystatin</title>
      </title-group>
      <pub-history>
        <date date-type="updated">
          <day>29</day>
          <month>4</month>
          <year>2020</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="livertox">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury</related-object>
      <related-object link-type="previous-part-link" source-id="livertox" document-id="NucleosideAnalogues" document-type="chapter">Nucleoside Analogues</related-object>
      <related-object link-type="next-part-link" source-id="livertox" document-id="ObeticholicAcid" document-type="chapter">Obeticholic Acid</related-object>
    </book-part-meta>
    <body>
      <sec id="Nystatin.OVERVIEW">
        <title>OVERVIEW</title>
        <sec id="Nystatin.Introduction" sec-type="pubmed-excerpt">
          <title>Introduction</title>
          <p>Nystatin is a topical and oral antifungal agent with activity against many species of yeast and candida albicans, which is used largely to treat skin and oropharyngeal candidiasis. Nystatin is not absorbed orally and has not been linked to drug induced liver injury.</p>
        </sec>
        <sec id="Nystatin.Background">
          <title>Background</title>
          <p>Nystatin (nye stat' in) is a polyene macrolide antibiotic that acts by binding to sterols in the plasma membranes of fungi causing the cells to leak, eventually leading to fungal cell death. Nystatin is indicated for the treatment of candidal infections of the skin, mucous membranes and gastrointestinal tract. It is not absorbed orally and thus not indicated for invasive fungal infections. Nystatin was approved by the FDA in 1971 and is currently widely used in the treatment of superficial candida infections of the skin, mucous membranes and gastrointestinal tract, including oropharyngeal candidiasis. Nystatin is available in multiple forms such as tablets, troches, powder for suspension, creams and ointments and varying concentrations which are usually measured in units. Nystatin is available in generic forms and under brand names such as Mycostatin, Nilstat, Nystat and Nystop. The recommended dose for oropharyngeal candidiasis is 500,000 to 1,000,000 units 3 to 5 times daily as oral suspension or tablets (dissolved in the mouth) for 1 to 2 weeks. Common side effects include metallic taste, dry mouth, anorexia and nausea.</p>
        </sec>
        <sec id="Nystatin.Hepatotoxicity">
          <title>Hepatotoxicity</title>
          <p>Nystatin therapy has been associated with a low rate of serum enzyme abnormalities, although it has been difficult to attribute these elevations to nystatin. Despite its use for several decades, there have been no convincing cases of acute hepatic injury linked to nystatin therapy. While nystatin is usually is not normally absorbed, low concentrations may enter the circulation in patients with inflammation and damage to the gastrointestinal tract. Nevertheless, nystatin is considered very safe and is unlikely to cause hepatic injury.</p>
          <p>Likelihood score: E (unlikely cause of clinically apparent liver injury).</p>
        </sec>
        <sec id="Nystatin.Mechanism_of_Injury">
          <title>Mechanism of Injury</title>
          <p>The absence of hepatotoxicity from nystatin is probably largely due to lack of absorption.</p>
          <p>Drug Class: <related-object link-type="booklink" source-id="livertox" document-id="AntifungalAgents" document-type="chapter">Antifungal Agents</related-object></p>
        </sec>
      </sec>
      <sec id="Nystatin.PRODUCT_INFORMATION">
        <title>PRODUCT INFORMATION</title>
        <p>
          <bold>REPRESENTATIVE TRADE NAMES</bold>
        </p>
        <p>Nystatin &#x02013; Generic, Mycostatin&#x000ae;, Nystat&#x000ae;</p>
        <p>
          <bold>DRUG CLASS</bold>
        </p>
        <p>Antifungal Agents</p>
        <p>
          <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=nystatin">COMPLETE LABELING</ext-link>
        </p>
        <p>Product labeling at DailyMed, National Library of Medicine, NIH</p>
      </sec>
      <sec id="Nystatin.CHEMICAL_FORMULA_AND_STRUCTURE">
        <title>CHEMICAL FORMULA AND STRUCTURE</title>
        <table-wrap id="Nystatin.Tc" orientation="portrait" position="anchor">
          <table frame="hsides" rules="groups">
            <tbody>
              <tr>
                <th id="hd_b_Nystatin.Tc_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">DRUG</th>
                <th id="hd_b_Nystatin.Tc_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">CAS REGISTRY NUMBER</th>
                <th id="hd_b_Nystatin.Tc_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1">MOLECULAR FORMULA</th>
                <th id="hd_b_Nystatin.Tc_1_1_1_4" valign="top" align="left" rowspan="1" colspan="1">STRUCTURE</th>
              </tr>
              <tr>
                <td headers="hd_b_Nystatin.Tc_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Nystatin</td>
                <td headers="hd_b_Nystatin.Tc_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pubchem" xlink:href="sid://134980330">1400-61-9</ext-link>
                </td>
                <td headers="hd_b_Nystatin.Tc_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1">C46-H83-N-O18<break/>C47-H75-N-O17</td>
                <td headers="hd_b_Nystatin.Tc_1_1_1_4" valign="top" align="left" rowspan="1" colspan="1">
                  <related-object link-type="ext-image-back-link" source-id="pubchem" document-id="134980330" document-id-type="sid" document-type="summary" object-id="134980330" object-id-type="sid" object-type="image"/>
                </td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="Nystatin.ANNOTATED_BIBLIOGRAPHY">
        <title>ANNOTATED BIBLIOGRAPHY</title>
        <p>References updated: 30 April 2020</p>
        <ref-list id="Nystatin.ANNOTATED_BIBLIOGRAPHY.reflist0">
          <ref id="Nystatin.REF.zimmerman.1999">
            <mixed-citation publication-type="book">Zimmerman HJ. Antifungal agents. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999, pp. 609-11.<annotation><p><italic toggle="yes">(Expert review of hepatotoxicity of antifungal agents published in 1999; nystatin is considered safe because it is not absorbed).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Nystatin.REF.moseley.2013">
            <mixed-citation publication-type="book">Moseley RH. Antifungal agents. Antibacterial and antifungal agents. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013, pp. 470-81.<annotation><p><italic toggle="yes">(Review of hepatotoxicity of antifungal agents does not discuss nystatin).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Nystatin.REF.rogers.2018">
            <mixed-citation publication-type="book">Rogers PD, Krysan DJ. Antifungal agents. In, Brunton LL, Hilal-Dandan R, Knollman BC, eds. Goodman &#x00026; Gilman&#x02019;s the pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill, 2018, pp. 1087-104.<annotation><p><italic toggle="yes">(Textbook of pharmacology and therapeutics).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Nystatin.REF.pons.1997.1204">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Pons</surname>
                  <given-names>V</given-names>
                </name>
                <name name-style="western">
                  <surname>Greenspan</surname>
                  <given-names>D</given-names>
                </name>
                <name name-style="western">
                  <surname>Lozada-Nur</surname>
                  <given-names>F</given-names>
                </name>
                <name name-style="western">
                  <surname>McPhail</surname>
                  <given-names>L</given-names>
                </name>
                <name name-style="western">
                  <surname>Gallant</surname>
                  <given-names>JE</given-names>
                </name>
                <name name-style="western">
                  <surname>Tunkel</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Johnson</surname>
                  <given-names>CC</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Oropharyngeal candidiasis in patients with AIDS: randomized comparison of fluconazole versus nystatin oral suspensions.</article-title>
              <source>Clin Infect Dis</source>
              <year>1997</year>
              <volume>24</volume>
              <fpage>1204</fpage>
              <lpage>7</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Controlled trial of 2 weeks of nystatin vs fluconazole in 167 patients with HIV infection and oropharyngeal candidiasis; side effects were minimal and included liver enzyme elevations in 2 subjects on fluconazole, but none on nystatin).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">9195083</pub-id>
            </element-citation>
          </ref>
          <ref id="Nystatin.REF.pons.1993.1311">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Pons</surname>
                  <given-names>V</given-names>
                </name>
                <name name-style="western">
                  <surname>Greenspan</surname>
                  <given-names>D</given-names>
                </name>
                <name name-style="western">
                  <surname>Debruin</surname>
                  <given-names>M</given-names>
                </name>
              </person-group>
              <article-title>Therapy for oropharyngeal candidiasis in HIV-infected patients: a randomized, prospective multicenter study of oral fluconazole versus clotrimazole troches. The Multicenter Study Group.</article-title>
              <source>J Acquir Immune Defic Syndr</source>
              <year>1993</year>
              <volume>6</volume>
              <fpage>1311</fpage>
              <lpage>6</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Trial of 14 days of fluconazole vs clotrimazole in 334 HIV infected patients with oropharyngeal candidiasis; 2 patients on fluconazole but none of clotrimazole were withdrawn for serum ALT elevations).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">8254467</pub-id>
            </element-citation>
          </ref>
          <ref id="Nystatin.REF.flynn.1995.322">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Flynn</surname>
                  <given-names>PM</given-names>
                </name>
                <name name-style="western">
                  <surname>Cunningham</surname>
                  <given-names>CK</given-names>
                </name>
                <name name-style="western">
                  <surname>Kerkering</surname>
                  <given-names>T</given-names>
                </name>
                <name name-style="western">
                  <surname>San Jorge</surname>
                  <given-names>AR</given-names>
                </name>
                <name name-style="western">
                  <surname>Peters</surname>
                  <given-names>VB</given-names>
                </name>
                <name name-style="western">
                  <surname>Pitel</surname>
                  <given-names>PA</given-names>
                </name>
                <name name-style="western">
                  <surname>Harris</surname>
                  <given-names>J</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Oropharyngeal candidiasis in immunocompromised children: a randomized, multicenter study of orally administered fluconazole suspension versus nystatin. The Multicenter Fluconazole Study Group.</article-title>
              <source>J Pediatr</source>
              <year>1995</year>
              <volume>127</volume>
              <fpage>322</fpage>
              <lpage>8</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Controlled trial of 14 days of fluconazole vs nystatin in 182 children with oropharyngeal candidiasis; liver test abnormalities occurred in 8% on nystatin vs 7% on fluconazole; no early discontinuations because of abnormalities).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">7636666</pub-id>
            </element-citation>
          </ref>
          <ref id="Nystatin.REF.young.1999.1208">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Young</surname>
                  <given-names>GA</given-names>
                </name>
                <name name-style="western">
                  <surname>Bosly</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Gibbs</surname>
                  <given-names>DL</given-names>
                </name>
                <name name-style="western">
                  <surname>Durrant</surname>
                  <given-names>S</given-names>
                </name>
              </person-group>
              <article-title>A double-blind comparison of fluconazole and nystatin in the prevention of candidiasis in patients with leukaemia. Antifungal Prophylaxis Study Group.</article-title>
              <source>Eur J Cancer</source>
              <year>1999</year>
              <volume>35</volume>
              <fpage>1208</fpage>
              <lpage>13</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Controlled trial of nystatin vs fluconazole for prevention of fungal infections in 160 patients with leukemia on chemotherapy; ALT elevations occurred in 24% of nystatin vs 24% of fluconazole treated patients, but most were attributed to other causes; one patient in each group developed &#x0201c;hepatitis&#x0201d;).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">10615231</pub-id>
            </element-citation>
          </ref>
          <ref id="Nystatin.REF8">
            <element-citation publication-type="journal">
              <article-title>Drugs for vulvovaginal candidiasis.</article-title>
              <source>Med Lett Drugs Ther</source>
              <year>2001</year>
              <volume>43</volume>
              <issue>1095</issue>
              <fpage>3</fpage>
              <lpage>4</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Concise summary of agents approved for therapy of vulvovaginal candidiasis including topical nystatin and the &#x0201c;azoles&#x0201d; such as clotrimazole, miconazole and butoconazole and oral fluconazole, mentions that nystatin is less effective than the azoles and that a single oral dose of fluconazole is often preferred by patients).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">11151090</pub-id>
            </element-citation>
          </ref>
          <ref id="Nystatin.REF9">
            <element-citation publication-type="journal">
              <article-title>Antifungal drugs.</article-title>
              <source>Treat Guidel Med Lett</source>
              <year>2009</year>
              <volume>7</volume>
              <fpage>95</fpage>
              <lpage>102</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Concise summary of therapy of fungal infections with recommendations on agents, dosage and duration of treatment and safety; nystatin is listed as a topical antifungal agent, but is not discussed).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">19940816</pub-id>
            </element-citation>
          </ref>
          <ref id="Nystatin.REF.pienaar.2010.cd003940">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Pienaar</surname>
                  <given-names>ED</given-names>
                </name>
                <name name-style="western">
                  <surname>Young</surname>
                  <given-names>T</given-names>
                </name>
                <name name-style="western">
                  <surname>Holmes</surname>
                  <given-names>H</given-names>
                </name>
              </person-group>
              <article-title>Interventions for the prevention and management of oropharyngeal candidiasis associated with HIV infection in adults and children.</article-title>
              <source>Cochrane Database Syst Rev</source>
              <year>2010</year>
              <volume>11</volume>
              <elocation-id>CD003940</elocation-id>
              <annotation>
                <p>
                  <italic toggle="yes">(Metaanalysis of trials comparing different regimens of therapy for oropharyngeal candidiasis; does not discuss hepatotoxicity).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">21069679</pub-id>
            </element-citation>
          </ref>
          <ref id="Nystatin.REF11">
            <element-citation publication-type="journal">
              <article-title>Antifungal drugs.</article-title>
              <source>Treat Guidel Med Lett</source>
              <year>2012</year>
              <volume>10</volume>
              <issue>120</issue>
              <fpage>61</fpage>
              <lpage>8</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Concise summary of therapy of fungal infections with recommendations on agents, dosage and duration of treatment and safety; nystatin is listed as a topical antifungal agent, but is not discussed).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">22825657</pub-id>
            </element-citation>
          </ref>
          <ref id="Nystatin.REF.pankhurst.2013.1304">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Pankhurst</surname>
                  <given-names>CL</given-names>
                </name>
              </person-group>
              <article-title>Candidiasis (oropharyngeal).</article-title>
              <source>BMJ Clin Evid</source>
              <year>2013</year>
              <volume>2013</volume>
              <fpage>1304</fpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Review of the evidence for efficacy of pharmacologic prevention and treatment or oropharyngeal candidiasis concludes that nystatin is less effective than oral and topical azole therapies but adverse events are uncommon; no mention of hepatotoxicity of nystatin).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">24209593</pub-id>
            </element-citation>
          </ref>
          <ref id="Nystatin.REF.mersal.2013.88">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Mersal</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Alzahrani</surname>
                  <given-names>I</given-names>
                </name>
                <name name-style="western">
                  <surname>Azzouz</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Alsubhi</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Alsawaigh</surname>
                  <given-names>H</given-names>
                </name>
                <name name-style="western">
                  <surname>Albshri</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Bajammal</surname>
                  <given-names>M</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Oral nystatin versus intravenous fluconazole as neonatal antifungal prophylaxis: non-inferiority trial.</article-title>
              <source>J Clin Neonatol</source>
              <year>2013</year>
              <volume>2</volume>
              <fpage>88</fpage>
              <lpage>92</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 57 premature neonates treated with oral nystatin or intravenous fluconazole [every 48-72 hours] for 6 weeks, none developed invasive candida infections and detection of candida in rectal swabs was uncommon in both groups; serum ALT levels were higher in those who received fluconazole but were all in the normal range).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">24049751</pub-id>
            </element-citation>
          </ref>
          <ref id="Nystatin.REF.fan.2015.95">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Fan</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Liu</surname>
                  <given-names>X</given-names>
                </name>
                <name name-style="western">
                  <surname>Wu</surname>
                  <given-names>C</given-names>
                </name>
                <name name-style="western">
                  <surname>Xu</surname>
                  <given-names>L</given-names>
                </name>
                <name name-style="western">
                  <surname>Li</surname>
                  <given-names>J</given-names>
                </name>
              </person-group>
              <article-title>Vaginal nystatin versus oral fluconazole for the treatment for recurrent vulvovaginal candidiasis.</article-title>
              <source>Mycopathologia</source>
              <year>2015</year>
              <volume>179</volume>
              <issue>1-2</issue>
              <fpage>95</fpage>
              <lpage>101</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 293 women with recurrent vulvovaginal candidiasis treated with vaginal nystatin suppositories for 14 days monthly or oral fluconazole [150 mg] once weekly, initial and 6 month follow up cure rates were similar in the two groups, and only one patient was intolerant of vaginal nystatin [burning and pain] and required switching to fluconazole).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">25416649</pub-id>
            </element-citation>
          </ref>
          <ref id="Nystatin.REF.chalasani.2015.1340">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Chalasani</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Bonkovsky</surname>
                  <given-names>HL</given-names>
                </name>
                <name name-style="western">
                  <surname>Fontana</surname>
                  <given-names>R</given-names>
                </name>
                <name name-style="western">
                  <surname>Lee</surname>
                  <given-names>W</given-names>
                </name>
                <name name-style="western">
                  <surname>Stolz</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Talwalkar</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Reddy</surname>
                  <given-names>KR</given-names>
                </name>
                <etal/>
                <collab>United States Drug Induced Liver Injury Network</collab>
              </person-group>
              <article-title>Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study.</article-title>
              <source>Gastroenterology</source>
              <year>2015</year>
              <volume>148</volume>
              <fpage>1340</fpage>
              <lpage>52.e7</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, 14 [1.6%] were attributed to an antifungal agent, but none to nystatin).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">25754159</pub-id>
            </element-citation>
          </ref>
          <ref id="Nystatin.REF.lyu.2016.1161">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Lyu</surname>
                  <given-names>X</given-names>
                </name>
                <name name-style="western">
                  <surname>Zhao</surname>
                  <given-names>C</given-names>
                </name>
                <name name-style="western">
                  <surname>Yan</surname>
                  <given-names>ZM</given-names>
                </name>
                <name name-style="western">
                  <surname>Hua</surname>
                  <given-names>H</given-names>
                </name>
              </person-group>
              <article-title>Efficacy of nystatin for the treatment of oral candidiasis: a systematic review and meta-analysis.</article-title>
              <source>Drug Des Devel Ther</source>
              <year>2016</year>
              <volume>10</volume>
              <fpage>1161</fpage>
              <lpage>71</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Systematic review of the published literature on the efficacy and safety of nystatin therapy for oral candidiasis identified 11 trials in 1148 patients [dental, pediatric, HIV-AIDS, cancer and miscellaneous groups], with cure rates of 14-77%; adverse events being reported in 8 studies common mentioned change in taste, and less commonly nausea, vomiting, diarrhea, anorexia and abdominal pain; no mention of ALT elevations or hepatotoxicity).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">27042008</pub-id>
            </element-citation>
          </ref>
        </ref-list>
      </sec>
      <sec sec-type="link-group" id="Nystatin.OTHER_REFERENCE_LINKS">
        <title>OTHER REFERENCE LINKS</title>
        <list list-type="order">
          <list-item>
            <label>1</label>
            <p>
              <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&#x00026;db=pubmed&#x00026;pubmedfilters=true&#x00026;term=(nystatin)+AND+Human%5BMH%5D+AND+(drug+induced+liver+injury+OR+jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%222010/1/1%22%5BEDat%5D:%222999/12/31%22%5BEDat%5D)">Recent References on Nystatin: from PubMed.gov</ext-link>
            </p>
          </list-item>
          <list-item>
            <label>2</label>
            <p>
              <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/results?term=nystatin">Trials on Nystatin: from ClinicalTrials.gov</ext-link>
            </p>
          </list-item>
        </list>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
